INTRODUCTION
About Us
Faculty Introduction
Technical Advisor
Giwon Kwon
Gi-Won Kwon, Key Account Manager, Product Manager Sartorius Korea Biotech
- kwongiwon88@gmail.com
Kyoungmin Kim
Kyoung Min Kim, CEO of BioSupport Co., Ltd.
- quality@biosupport.co.kr
Kidong Kim
Ki Dong KIM, CEO
- kdkim57@naver.com
Youngtae Kim
Youngtae Kim, Sartorius Korea Biotech LLC Director
- Ryan.kim@sartorius.co.kr
Hyekyoung Min
Hyekyoung Min, MinLab, Director
- bsmhg61@naver.com
Deokseok Oh
DeokSeok Oh, Janssen, Head of QA
- ejrtjr@gmail.com
Youngha Yu
Youngha Yu, MBA
- youngha.yu@samsung.com
Sanghoon Lee
SANG HOON LEE, Ph.D.
- sang.lee@ablbio.com
Janghan Lee
Janghan Lee
- hanymir@kbiohealth.kr
Hoesuk Lee
Hoe-Suk Lee, Post-Doc Researcher, Department of Biochemical Engineering, Gangneung-Wonju National University
- hsl0828@snu.ac.kr
Jaehyuk JeonProfessor
- jjh0209@itp.or.kr
Jinhyun Jun
Jun, Jin Hyun
- junjh55@hanmail.net
Gi-Won Kwon
Gi-Won Kwon, Key Account Manager, Product Manager Sartorius Korea Biotech
- kwongiwon88@gmail.com
EDUCATION
- 2007 - 2014Kangwon National University(Kangwon-do, Korea)
Bachelor’s in biotechnology engineering
PROFESSIONAL CAREER SUMMARY
- Dec. 2017 ~ PresentSartorius Korea Biotech
Key Account Manager, Product Manager / Life Science Research Team - Dec. 2015 ~
Nov. 2017Korea Biotechnology Industry Organization (KoreaBIO)
Associate Manager / Bio Specialist Training Unit - Nov. 2013 ~
Nov. 2015EmageneScience
Technical Sales Engineer / Life Science Department
Kyoung Min Kim
Kyoung Min Kim, CEO of BioSupport Co., Ltd.
- quality@biosupport.co.kr
Education
- 1987~1993Bachelor's Degree in Food and Life Science Engineering, Sungkyunkwan University
- 1993~1996Master's Degree in Food and Life Science Engineering, Sungkyunkwan University
- 1994~1995Special Researcher at Micro-lab, Okayama University, Japan
Professional Experience
- 2016~PresentCEO, BioSupport Co., Ltd.
- 2003~PresentCEO, BioSupport Co., Ltd.
- 2016~2021CEO, Korea Pharmaceutical Technology Education Center (KPTEC)
- 2018~PresentSenior Vice President, Parenteral Drug Association (PDA) Korea
Key Activities
- 2021~PresentAdvisory Board Member, K-NIBRT Project
- 2007~PresentInstructor for GMP and Validation Courses, Korea Pharmaceutical Technology Education Center (KPTEC)
- 2014~PresentGMP Course Instructor, Korea Health Industry Development Institute
- 2013~2021Operating Committee Member, Korea PDA and PharmTech
- 2019~2020Instructor, Pharmacy Practical Training Program, College of Pharmacy, Ewha Womans University
Ki Dong KIM
Kapable FnC Co.Ltd. (CEO)
- kdkim57@naver.com
EDUCATION
- 1987-1991University of Reading UK Dept. PhysioLogy & Biochemistry
- 1982-1985Reproductive Physiology, Graduate School, Korea University (MSc)
- 1976-1982Dept. Animal Science, Korea University (BSc)
EXPERIENCE
- 2021-PresentKapable FnC Co.Ltd. (CEO)
- 2017-2020Nexbio Co. Ltd. (Scientific Advisor)
- 2017-2020BIOXSINE KOREA (CTO)
- 2015-2018Nadamcos Co. Ltd. (Technology Advisor)
- 2014-2015Luvama Nature Co. Ltd (CTO)
- 2009-2014BMBS Co. Ltd (CEO)
- 2002-2008Imgen Co. Ltd. (CEO)
- 2000-2002
- 1995-2008School of Life Sciences, Korea University (Lecturer)
- 1990-1994University CoLLege London UK, MedicaL SchooL (Dept. MoLecuLar Endocrino
Youngtae Kim
Youngtae Kim, Sartorius Korea Biotech LLC Director
- Ryan.kim@sartorius.co.kr
Education
- 2001-2008Sungkyunkwan University, Bachelor's degree in Chemical Engineering
- 2010-2013Ministry of Employment and Labor, Specially Appointed Lecturer for Bio-process Core Technology Professional Training Project
SAMSUNG Biologics, SK Chemical, Green Cross, etc. Specially Appointed Lecturer for Pharmaceutical Companies - 2022Serving as an instructor for the training of MFDS GMP inspectors
- 2008-PresentSartorius Biotech Co., Ltd
Research and Publications
- 2012.07 Write an article about ParmTech
- 2015-2016Write an article about sureGMP (vol. 16,17,18)
- 2019High School Textbook, 'Biosimilar' Publication
Hyekyoung Min
Hyekyoung Min, MinLab, Director
- bsmhg61@naver.com
Education
- 1996.02Master's Degree in Biology, Graduate School, Soonchunhyang University
- 2007.02Doctor of Philosophy (Ph.D.) in Molecular Medicine, Graduate School, Korea University
Professional Experience
- 2018~PresentDirector,MinLab
- 2017~2020Director ,Corporation Junggyum
- 2016~2017Deputy Director,Medical Device Research Division,
Pharmaceuticals and Medical Devices Research Department, National Institute of Food and Drug Safety Evaluation - 2012Senior Scientific Officer, Imported Food Analysis Division,Hazardous Substances Analysis Division ,Center fof Food & Drug Analysis ,Gyeongin Regional of Ministry of Food and Drug Safety
- 2011Deputy Director, InVitro Diagnostic Medical Device T/F Team, Medical Device Evaluation Department, National Institute of Food and Drug Safety Evaluation
- 2009Deputy Director, Biological Division, Biopharmaceuticals and Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation
- 2006Scientific officer, Biological Division, Biopharmaceuticals and Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation
DeokSeok Oh
DeokSeok Oh, Technical Advisor
- ejrtjr@gmail.com
Education
- 1998-2007Bachelor of Science in Biological Sciences Seoul National University Seoul, Korea
Work Experience
- Head of QA
- 2020-PresentJanssen Lead of NPI & Commercial Manage three teams (QA NPI/Product, QA Commercial & QA Lab) Certified QL (Quality Leader) for investigation / Certified Auditor FDA inspection in 2022 & 2023
- Manager of MSAT (Manufacturing Science and Technology
- 2016-2020Janssen Lead of Aseptic & Sterilization Technical transfer of new product from Janssen R&D Member of aseptic manufacturing council, J&J MQSA J&J AP101 trainer (topic: Aseptic Process Simulation)/J&J AP201 trainer (topic: Contamination Investigation)
- Validation & Quality Engineering
- 2014-2015Janssen Aseptic Process Simulation Cleaning Validation
- QA Manager of Global Pharma TFT
- 2012-2014Kolon Group Overseas pharmaceutical project in West Africa
- Part Leader of Validation & Compliance QA
- 206-2011Hanmi Pharmacetical Plant construction project (cephalosporin) New line project (power injection) MHRA (UK) inspection in 2008 & 2011
Professional Experience
- PDASteering committee member of PDA Asia Presentation at PDA conference (topic: APS intervention and smoke study) PDA Asia pacific service appreciation award, April 2023
Vice President of PDA Korea chapter Presentation at PDA workshop (topic: Contamination Control Strategy) - K-NIBRTPresentation at K-NIBRT (topic: Fill and Finish) PQM
- PQMLocal community member with Korean Health Authority Award from MFDS Gyeongin regional office, December 2015
Youngha Yu
Youngha Yu, MBA
- youngha.yu@samsung.com
Summary
- Over 12 years of experience in biopharmaceutical, pharmaceutical, and CDMO sectors
- Boundary spanning leadership through experiences in manufacturing operations, quality management, ITSM, DX, PI, etc.
경력
- [Samsung Biologics] Business Innovation / Unit Lead
- Manage MES (Manufacturing Execution System) development & operations
- Project management of DX (Digital Transformation) & PI (Process Innovation)
- Manage CSV (Computer System Validation) & CSA (Computer Software Assurance) process
- Manufacturing innovation TF / In charge of PMO management
- Quality Assurance
- CMC quality assurance for Drug Product (DP)
- DP (Drug Product) technical quality
- DP (Drug Product) quality operations, general
- In charge of clinical product introduction & management
- [SK biotek, an SK pharmteco company] Quality Assurance
- DS (Drug Substance) quality operations, general
- R&D quality operations, general
- Batch disposition & warehouse management
- In charge of SCQ (Supply Chain Quality) management
- In charge of CMO management / Lead auditor
- [CKD (Chong Kun Dang) Pharmaceuticals] DP Manufacturing Operations / Manufacturing Supervisor
- In charge of DP (Drug Product) manufacturing operations management
- In charge of global plant expansion project for EU market
- In charge of sterile fill-finish and manufacturing technology management
- Managed and experienced from investigational and clinical products to commercial products / ETC & OTC
- Managed pharmaceutical formulations
- SVPs (Small Volume Parenteral Solutions)
- LVPs (Large Volume Parenteral Solutions)
- Ophthalmic solutions (Eye drops)
- Oral liquids (drink pouches / bottles) - Managed pharmaceutical manufacturing system & technology
- RABS (Restricted Access Barrier System)
- BFS (Blow-Fill-Seal)
- PAT (Process Analytical Technology)
- Lyophilization
- Pharmaceutical packaging
- Serialization (Track & Trace)
Other Experience
- [PDA Korea Chapter] Regional Operations Manager / Board Director
- Provide support to the regional country chapter and host annual conferences
- High-quality interpretation and education of new regulations
- Presenting a new approach and guideline for the introduction of new technology into the industry
- Editorial director in the bioindustry field of PharmTech, a journal specializing in GxP regulations and biopharmaceutical manufacturing technology
SANG HOON LEE
SANG HOON LEE, Ph.D.
- sang.lee@ablbio.com
EDUCATION
- Ph.D. in Molecular, Cellular and Developmental Biology, The Ohio State University, Columbus, OH
- M.S. in Developmental Biology, Seoul National University, Seoul, Korea
- B.S. in Biology Education, Seoul National University, Seoul, Korea
EXPERIENCE
- ABL Bio, South Korea CEO and FOUNDER 2016- Present
- CEO and Founder of ABL Bio (KOSDAQ 298380)
- Lead fund raising
- Successful IPO in KOSDAQ market in 34 months (Dec, 2018): 90 MM USD
- Lead, build, and manage entire business operations
- Hanwha Chemical, South Korea HEAD OF BIO DIVISION & SENIOR VICE PRESIDENT (2013-2016)
- Head of Bio Division - General Management of Bio organization and operation - Lead R&D including biosimilar and new drug discovery - Scientific and strategic leader - Lead cGMP facility at Osong cGMP facility - Manage operating and capital budgets
- PharmAbcine, Daejun, South Korea CO-FOUNDER and CSO (2009-2013)
- Head of R&D and lead Business Development
- Responsible for fund raising
- Exelixis, South San Francisco, CA SENIOR SCIENTIST II/ ASSOCIATE DIRECTOR, MOLECULAR & CELLULAR PHARMACOLOGY (2008-2009)
- Lead target validation and lead optimization for oncology discovery projects
- Lead in vitro mechanism of action (MOA) study, developing mechanistic cell-based assays and PK/PD studies for oncology discovery projects
- Support translational research for PI3K inhibitor (XL147), PI3K/mTOR dual inhibitor (XL765), IGF1R inhibitor (XL228) and S1P1R antagonist
- Genentech, Inc., South San Francisco, CA GROUP LEADER/SCIENTIST, ONCOLOGY PHARMACODYNAMIC BIOMARKERS (2005-2008)
- Group leader for Oncology Pharmacodynamic Biomarker Group
- Sub-team leader of oncology diagnostic team to provide diagnostics strategy for the discovery and development of predictive biomarkers
- Managed 7 peoples including 2 scientists and 5 research associates
- Oversee development and implementation of quantitative RT-PCR including TLDA array, immunoassays, Luminex, Rules based medicine (RBM), Meso Scale Discovery (MSD), immunohistochemistry and FACS assay including intracellular phospho-flow cytometry assays into Phase I trial
- Participate in biomarker strategic reviews of Genentech late stage research and early development pipelines for oncology and hematological oncology area
- AstraZeneca R&D Boston, Waltham, MA PRINCIPAL SCIENTIST, CANCER BIOSCIENCE (2004 - 2005)
- Project leader of AstraZeneca and Abgenix collaboration for developing therapeutic monoclonal antibodies
- Involved in global AstraZeneca global team for novel oncology target discovery
- Lead planning and implementation of strategies for tissue bank specimens from preclinical models and support translational research
- Chiron Corporation, Emeryville, CA (Currently Novartis) PRINCIPAL SCIENTIST, TRANSLATIONAL MEDICINE (2002-2004)
- Lead proof-of-concept, preclinical PK/PD, pharmacodynamic biomarker discovery and development for CHIR-258, multiple receptor tyrosine kinase small molecule inhibitor and support clinical development and biomarker strategies (TKI-258, currently in Phase II by Novartis ).
- Oversee and responsible for in vitro MOA, preclinical PK/PD, cell-based pharmacodynamic biomarker discovery for CHIR-265 (Raf and RTK inhibitor; currently in Phase II by Novartis)
- Lead MOA, Biomarker and Translational Research for anti-CD40 monoclonal antibody, HCD-122 (currently in Phase II by Novartis)
- Participated in strategies for publication and presented data at relevant scientific meetings for small molecule kinase inhibitor CHIR-258 and anti-CD40 monoclonal antibody
- Managed up to 10 people including 2 scientists and 8 research associates
- RESEARCH SCIENTIST II, CANCER PHARMACOLOGY (2000-2002)
- Responsible for in vitro and in vivo pharmacology studies for kinase small molecule inhibitor projects
- Planned and performed PK/PD study using xenograft tumor models
- Conducted research program for in vitro and in vivo studies for protein-based anti-angiogenesis therapy
- Evaluated novel anti-angiogenic therapies, internal and external
- Led early discovery research project: Regulation of VEGF by beta-Catenin in colon cancer
- Study erythropoietin receptor signaling on vasculogenesis and angiogenesis using knockout mice
Janghan Lee
Technical Advisor
- hanymir@kbiohealth.kr
Education
- 2020~2022Ph.D. (cand.): Industrial pharmacy, Chungbuk national university
- 2008~2010M.S.: Molecular biotechnology, Korea university
- 2002~2007B.S.: Biotechnology, Sejong university
Work experience
- 2015~presentNew drug development center, Osong medical innovation foundation
- 2012~2015R&D center, Hanwha chemical
- 2010~2012R&D center, TS corporation
Research / interest field
- Therapeutic protein, antibody, vaccine and cell & gene therapy (Biopharmaceuticals)
- Upstream process development & characterization (Quality by design)
- Bioreactor scale-up & tech. transfer (Manufacturing platform technology)
Hoe-Suk Lee
Technical Advisor
- HSL0828@snu.ac.kr
Academic Experiences
- 2008.08BSc Biochemistry. Department of Life Science, Imperial College London, United Kingdom
- 2019.08PhD Bioengineering. Interdisciplinary Program of Bioengineering Seoul National University, Republic of Korea
- 2019.09 ~ CurrentPost-Doc Researcher. Department of Biochemical Engineering, Gangneung-Wonju National University, Republic of Korea
PhD Thesis
- Study on the Structure-based Engineering of Hydroxy Acid Dehydrogenases for Improvement of Substrate Specificity
Research Area
- Biochemical engineering
- Protein and enzyme engineering
- In silico rational design of proteins
- Directed evolution of proteins
- In vitro / In vivo engineering of biocatalyst
- Development of proteins and transformed cells for industrial and medical applications
Jun, Jin Hyun
Jun, Jin Hyun, Department of Biomedical Laboratory Science, College of Health Sciences, Eulji University
- junjh55@hanmail.net
Education
- 1989.02Hanyang University, Department of Life Science, Bachelor's Degree
- 1993.02Hanyang University, Department of Life Science, Master's Degree in Developmental Biology
- 1999.08Ph.D. in Developmental Biology, Department of Life Science, Hanyang University
Experience
- 1993.08.01~2008.02.28Director of Reproductive Biology and Infertility Research Laboratory, Cheil General Hospital, Seoul
- 2000.03.01~2001.08.15University of Pennsylvania, CRRWH Post-Doc Fellow
- 2008.03.01~PresentProfessor of Biomedical Laboratory Science, Eulji University
- 2018.01.01~2022.12.31Vice-president of the Korean Society for Men's Health
- 2021.01.01~2022.12.31President of the Korean Society for Reproductive Immunology
- 2022.01.01~PresentPresident of the Korean Society for Biomedical Laboratory Sciences
JEON JAE HYUK
Professor
- jjh0209@itp.or.kr
- -
- -
Education
- 2024 Phd student, School of Inha University, Biological Sciences and Bioengineering
- 2015 MS, Soonchunhyang University, Marine Biotechnology
- 2009 BS, Soonchunhyang University, Marine Biotechnology
EMPLOYMENT EXPERIENCE
- 2023 Employer C: Bio Center, Incheon Technopark, Senior Researcher
- 2021 Employer B: Plasma Fractionation Center, Korean Red Cross, Researcher
- 2017 Employer A: National Marine Biodiversity Institute of Korea, Junior Researcher